Virginia Smith, APRN
Psychiatric/Mental Health · Omaha, NENPI 1568827095
Payments from drug & device makers
Across 576 payments — averaging $19.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$2K
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$662
- Harmony Biosciences LLC$615
- plus $4K from 26 others
What the payments were for
- Food & beverage$11,22299%
- Education$1011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 74 | $2,051 |
| AbbVie | 104 | $1,575 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 60 | $1,172 |
| Otsuka America Pharmaceutical, Inc. | 61 | $1,152 |
| Teva Pharmaceuticals USA, Inc. | 35 | $662 |
| Harmony Biosciences LLC | 29 | $615 |
| Neurocrine Biosciences, Inc. | 21 | $555 |
| Vanda Pharmaceuticals Inc. | 22 | $470 |
| Lundbeck LLC | 24 | $428 |
| Johnson & Johnson | 22 | $387 |
| Supernus Pharmaceuticals, Inc. | 17 | $326 |
| Axsome Therapeutics, Inc. | 13 | $238 |
| Idorsia Pharmaceuticals US Inc | 9 | $216 |
| E.r. Squibb & Sons, L.L.C. | 6 | $215 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $161 |
| Sunovion Pharmaceuticals Inc. | 14 | $160 |
| Almatica Pharma LLC | 8 | $147 |
| Bausch Health US, LLC | 8 | $127 |
| Corium, LLC | 6 | $107 |
| Neos Therapeutics, LP | 7 | $107 |
| Eisai Inc. | 4 | $74 |
| Noven Therapeutics, LLC | 4 | $68 |
| Indivior Inc. | 3 | $60 |
| Collegium Pharmaceutical, Inc. | 3 | $47 |
| Avanir Pharmaceuticals, Inc. | 3 | $40 |
| Ironshore Pharmaceuticals Inc. | 2 | $33 |
| Azurity Pharmaceuticals, Inc. | 2 | $27 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $27 |
| Merck | 2 | $25 |
| Adlon Therapeutics L.p. | 2 | $25 |
| Tris Pharma Inc | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,323 in reported general payments places this provider in the 95th percentile of 255 psychiatric/mental health providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 108 | $149,631 |
| IngrezzaValbenazine Tosylate | 13 | $113,900 |
| LybalviOlanzapine/Samidorphan Malate | 36 | $84,992 |
| AristadaAripiprazole Lauroxil | 24 | $78,759 |
| Abilify MaintenaAripiprazole | 12 | $33,293 |
| Clomipramine Hcl | 100 | $21,311 |
| Paliperidone ErPaliperidone | 75 | $18,211 |
| FetzimaLevomilnacipran Hcl | 26 | $13,370 |
| Vilazodone Hcl | 136 | $12,649 |
| QuviviqDaridorexant Hcl | 25 | $11,868 |
| Lurasidone Hcl | 33 | $10,642 |
| NuedextaDextromethorphan Hbr/Quinidine | 14 | $10,318 |
| BelsomraSuvorexant | 13 | $5,815 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,556 |
| Ziprasidone Hcl | 35 | $4,145 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Lybalvi, Aristada | $2,051 | $163,75160 claims |
| AbbVieVraylar, Fetzima | $1,575 | $163,001134 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $555 | $113,90013 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $1,152 | $33,29312 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $216 | $11,86825 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $40 | $10,31814 claims |
| MerckBelsomra | $25 | $5,81513 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $161 | $4,55612 claims |
| Almatica Pharma LLCSertraline Hcl | $147 | $1,822198 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 255 psychiatric/mental health providers in Nebraska.
Other psychiatric/mental health in Omaha
- Janelle HillOmaha$24K
- Kristi BoseOmaha$13K
- Robert LundholmOmaha$12K
- Christina HadleyOmaha$11K
- Julie ZulkoskyOmaha$8K
- John RamseyOmaha$8K
- M Joyce SasseOmaha$7K
- Molly PetersenOmaha$6K
- Salina AndersonOmaha$6K
- Heather WilhelmOmaha$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.